The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison
Summary:
The role of allogeneic bone marrow transplantation (alloBMT) in adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) remains controversial. At our institution, the policy is to offer alloBMT to ALL patients in CR1 up to the age of 55 years if a related donor is available. In addition, unrelated donor transplants are offered to patients with Philadelphia (Ph þ ) ALL. We report the results on 92 patients with ALL treated according to this policy from September 1992 to October 2001. Of the 87 patients achieving CR1, the comparison of patients with (n ¼ 48) or without donors (n ¼ 39) was done using an intention-to-treat approach. Of the 48 patients with donors (39 related and nine unrelated), 35 (73%) received alloBMT in CR1. No significant difference in 3-year event-free survival (EFS) (40 vs 39%, P ¼ 0.74) or overall survival (OS) (46 vs 58%, P ¼ 0.41) was seen in 'donor' vs 'no-donor' groups. For Ph þ patients, 3-year EFS and OS in 'donor' group were 46 and 57%, respectively, none of the patients in 'nodonor' group survived beyond 3 years. With our treatment strategy, 3-year OS of Ph þ patients was equivalent to Ph-negative (PhÀ) patients (51 vs 52%, P ¼ 0.77). In conclusion, our data show that the policy of performing alloBMT if a sibling donor is available has not resulted in better outcome in PhÀ patients. However, despite intensive induction and consolidation chemotherapy, the majority of patients relapse and 5-year relapse-free survival (RFS) ranges from 30 to 50%. [1] [2] [3] [4] [5] [6] [7] [8] [9] Allogeneic bone marrow transplantation (alloBMT) is the most intensive postremission therapy and has been used in adult ALL for over 20 years. However, the role of alloBMT remains controversial as demonstrated by conflicting results from various studies. [10] [11] [12] [13] [14] The rarity of this disease in adults precludes any possibility of a randomized controlled trial, adding to the difficulty in assessing the utility of this approach in ALL patients.
Previous case-controlled studies did not show an advantage of alloBMT over chemotherapy. 10, 11 No difference was observed in a comparison of 484 patients treated with chemotherapy alone at 44 hospitals in Germany and 251 alloBMT recipients in CR1 that were reported to IBMTR registry. Another study of similar design between the IBMTR registry and the Japanese adult leukemia study group showed an advantage of alloBMT only in patients with age p30 years. 13 Various transplant series have described a better long-term survival with alloBMT as postremission therapy. 15, 16 The main shortcomings of these studies are related to patient selection bias, small numbers of patients and exclusion of patients whose remission is too short to allow transplant in CR1. Based on genetic randomization, comparison of alloBMT (n ¼ 116) was done with the control group (n ¼ 141, treated with chemotherapy or autologous BMT) in CR1 in a multicenter study (LALA 87) involving 43 French and Belgian centers. The 5-year survival rates were not significantly different in the alloBMT and control arms (48 vs 35%, P ¼ 0.08).
However, when results were analyzed according to risk stratification, 5-year survival was significantly superior in the alloBMT arm compared to the control arm for the high-risk group only (44 vs 20%, P ¼ 0.03). In the longterm follow up of this study, the same trend was maintained. 6 In a Delphi-panel analysis, only Philadelphia chromosome (Ph)-positive (Ph þ ) patients were judged to be appropriate for alloBMT using an HLA-identical or unrelated donor. 17 More recently, preliminary results of an International ALL study (collaborative study between MRC/ECOG) on Ph-negative (PhÀ) patients have reported superiority of alloBMT over chemotherapy in all risk groups. 14 At our institution, it is the treatment policy to offer alloBMT to adult patients with ALL in CR1 up to the age of 55 years if a related donor (either HLA-identical or oneantigen mismatched) is available. In addition, transplants from unrelated donors are offered to patients with Ph þ ALL in CR1. Patients without a donor are treated with intensification and maintenance therapy for 2 years after CR1.
The main objective of this retrospective study was to evaluate the outcome of adult ALL based on this treatment strategy, and to determine whether or not all patients in first CR with suitable donor should receive alloBMT. The other objective was to identify if any subgroup of patients benefit preferentially from alloBMT or chemotherapy.
Materials and methods

Patients
We analyzed the clinical course of all the newly diagnosed adult patients with ALL, between the ages 16-54 years treated at Princess Margaret Hospital/University Health Network (PMH), Toronto from September 1992 to October 2001. During this period, 112 new patients with the diagnosis of ALL were registered at PMH. Patients with mature B-ALL (n ¼ 13) (expression of surface immunoglobulin (sIg) 420%/L 3 morphology) and biphenotypic acute leukemia (n ¼ 2) diagnosed according to the criteria of Catovsky et al 18 were excluded. Patients whose chemotherapy was modified due to associated comorbid conditions (n ¼ 3), lost to follow-up (n ¼ 1) and Jehovah's witness (n ¼ 1) were also excluded from this study. After these exclusions, 92 patients were eligible for this study. This study was approved by University Health NetworkResearch and Ethics Board (UHN-REB). Information was collected from the databases of the Leukemia & alloBMT service and chart studies.
PMH is the referral center for the treatment of acute leukemia for the Greater Toronto Area serving a population of approximately 4 million; 80% of patients with acute leukemia from this area are treated at PMH. This study only included patients who received their initial chemotherapy and subsequent treatments at PMH. Patients who received their initial chemotherapy elsewhere and were referred to PMH only for alloBMT were not part of this study.
Diagnostic work-up
The diagnosis of ALL was confirmed by cytology and cytochemical characteristics of blood film and bone marrow according to FAB criteria. 19 .
Based on immunophenotyping, patients were diagnosed as Pre-B-ALL, mature B-ALL and T-ALL. 20 Cytogenetic studies were performed according to established criteria; 20 metaphases were analyzed whenever possible. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature. The cytogenetics abnormalities, t (9;22) and t (4;11), were defined as high risk, 21, 22 all other cytogenetic abnormalities were considered as standard-risk.
A diagnostic lumbar puncture was performed at presentation and results were categorized as no Central nervous system (CNS) involvement, CNS involvement (45 WBC/ml in CSF with morphologically unequivocal blast cells) or suspicious involvement (p5 WBC/ml in CSF with equivocal morphology). HLA typing of the patients and potential sibling donors was initiated at the time of diagnosis. For Ph þ patients who did not have a sibling donor, an unrelated donor search was initiated at the earliest opportunity.
Treatment designation
Patients with an appropriate donor (related for PhÀ ALL and related/unrelated for Ph þ ALL) were assigned to the 'donor' group and patients without a donor were designated as 'no donor' group. All analyses were carried out using the intention-to-treat rule; that is, the outcome for each patient was counted against the treatment group to which he/she was assigned based on the availability of a donor, regardless of whether he/she received the respective therapy.
Induction therapy
During the study period, patients were treated with different treatment protocols according to the policy established by the leukemia group. The backbone of these protocols was multiagent chemotherapy consisting of at least four drugs -vincristine, prednisone or dexamethasone, doxorubicin and L-asparaginase. A proportion of patients (46%) also received high-dose methotrexate (MTX) during induction therapy. CNS prophylaxis was given with intrathecal methotrexate and fractionated cranial radiation, 12-18 Gy. In patients without CNS disease, cranial radiation was avoided if eligible for alloBMT. There were no significant differences in the 'donor' vs 'no donor' groups with regard to induction therapy protocols.
Postremission treatments
'No donor' group. After achieving a remission, patients were treated with multiagent consolidation treatment, CNS prophylaxis, late intensification and maintenance treatment for a total of 2 years. None of the patients received autologous BMT (ABMT).
'Donor' group. Patients eligible for alloBMT received 2-4 courses of intensification therapy. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/day for 3 days) and total body irradiation (1200 cGy in six fractions over 3 days) with partial lung shielding in 92% of patients. Unmanipulated bone marrow grafts were used, except for ABO incompatibility where red cell depletion was applied. Graft-versus-host disease (GVHD) prophylaxis included short-course of MTX and standard dose cyclosporine (CSA) in 82% patients; 23 18% of patients received steroids in addition to MTX and CSA. The median time to transplant was 6 months from the date of diagnosis.
Criteria for response
CR was defined as the reconstitution of a normocellular BM with o5% blast cells along with PB neutrophil count X1.5 Â 10 9 /l and platelets X100 Â 10 9 /l. Patients who had more than 5% blasts after one course of induction chemotherapy were given additional chemotherapy. Patients who were unable to achieve a CR with additional chemotherapy were defined as having resistant disease. Event-free survival (EFS) was defined as the time from confirmation of CR to relapse (hematological/CNS or extramedullary) or death from any cause. Overall survival (OS) was defined as the time from diagnosis to last follow up or death. All data were updated on 31 March 2003, when the median follow up for the living patients was 52 months.
Risk stratification
The risk stratification criteria were modified from the previously published reports.
1,24-26 Based on these, the patients were categorized as high-risk and standard-risk. Patients with at least one of the following prognostic factors were considered to have high-risk ALL:
Patients with none of the above prognostic factors were designated as standard-risk ALL.
Statistical analysis
Characteristics of patients were described by proportion, ratio, median, range and 95% confidence interval (CI), and compared by w 2 tests and student t-tests as appropriate. The P-values were determined according to the two-sided test. The Kaplan-Meier method was used to estimate the EFS and OS rates. 27 The analysis was carried out on an intention-to-treat basis. Cumulative relapse rates were estimated using Cmprsk package in R software. The competing risk of dying from other causes was considered in the estimation of cumulative relapse rate. 28 For univariate analysis, log-rank tests were used to examine the association between EFS or OS and patient characteristics at diagnosis. All analyses were done in SAS 8.01.
Results
Response to induction therapy
Of the 92 patients, 87(95%) achieved a CR with induction chemotherapy. After one course of induction chemotherapy, 65 patients (71%) obtained CR, additional chemotherapy was required in 22 patients (24%). There was no difference in the remission rates to different induction regimens. The causes of induction treatment failure were resistant disease (n ¼ 3) and death due to infectious complications during the period of hypoplasia (n ¼ 2). Of the 87 CR patients, 39 patients did not have a suitably matched donor and comprised the 'no donor' group. In total, 35 patients had HLA-identical related donors, four patients had a related one antigen-mismatched donor and nine patients (all Ph þ ) had a matched unrelated donor. These 48 patients were designated as 'donor' group.
Patient characteristics. The median age of 87 patients achieving CR was 32 years. Patient and disease characteristics of 'donor' and 'no donor' groups are summarized in Table 1 . There were no significant differences in the two groups with respect to age, gender, median WBC count, immunophenotype, risk stratification, CNS involvement, extramedullary features and response to chemotherapy. Based on the risk criteria, 76 patients (87%) were classifiable as either high-risk (n ¼ 46) or standard-risk (n ¼ 30). Risk stratification could not be done in 11 patients (13%) due to partially missing information.
Cytogenetics
Pretreatment cytogenetic results were available on 74 patients (85%). In 13 patients (15%), cytogenetics testing was not done. Cytogenetic results were not evaluable in 10 patients (11%) either due to poor quality metaphases, suboptimal number of metaphases or failure to grow metaphases. Of the 64 patients (74%) with evaluable karyotype, abnormal cytogenetics was seen in 38 patients (59%). A total of 18 patients with abnormal cytogenetics were categorized as high-risk (17 Ph þ patients and one patient with t(4;11)). All other cytogenetic abnormalities (20 patients) were categorized as standard-risk. The 'donor' group had more patients with high-risk cytogenetics, as unrelated donors were available for 9 Ph þ patients.
Outcome in the 'donor' group. This group included patients with related donors that were HLA identical (n ¼ 35) or antigen mismatched at one locus (n ¼ 4) as well as unrelated (n ¼ 9). Based on risk stratification, there were 14 patients (29%) in the standard-risk category, 28 patients (58%) in the high-risk category and risk was not evaluable in six patients (13%). Of the 48 patients with donors, 35 patients (73%) received alloBMT in CR1. Of these 35 patients, 10 patients died of transplant-related complications (Table 2) , five due to relapse, one of causes unrelated to treatment or relapse. Five patients were not transplanted due to deterioration in performance status (n ¼ 1), active fungal infection (n ¼ 1) and patient refusal (n ¼ 3). Eight patients relapsed before proceeding to alloBMT. Seven of Role of alloBMT in adult ALL in CR1 V Gupta et al these patients received an alloBMT in CR2 and one patient in aplasia following salvage treatment. Of these eight patients, seven died of complications related to transplant (n ¼ 4) or relapse (n ¼ 3).
Outcome in the 'no donor' group. Of the 39 patients in the 'no donor' group, 16 patients (41%) were in the standardrisk category and 18 (46%) in the high-risk category. Risk was not evaluable in five patients (13%). There were no deaths related to toxicity secondary to consolidation or maintenance chemotherapy. A total of 21 patients (54%) relapsed (standard-risk category (n ¼ 5), high-risk category (n ¼ 13) and risk not evaluable (n ¼ 3)). Of the relapsing patients, six patients underwent a rescue transplant from unrelated donors in CR2. There were four deaths in this subgroup (transplant-related complications (n ¼ 2), relapse (n ¼ 2)).
EFS and OS
Using an intention-to-treat approach, there was no statistically significant difference in the EFS (P ¼ 0.74) or OS (P ¼ 0.41) in the 'donor' vs 'no donor' groups ( Figures 1  and 2 ). No differences in EFS or OS were observed in a subgroup analysis based on risk stratification (Tables 3 and  4 ). After excluding Ph þ patients (n ¼ 17), there was no significant difference in 3-year EFS (37% (95% CI 20-53) vs 44% (95% CI 27-61), P ¼ 0.42) (Figure 3 ) or OS (43% (95% CI 26-60) vs 60% (95% CI 43-78), P ¼ 0.20) in the 'donor' (n ¼ 34) vs 'no donor' (n ¼ 36) groups. When the outcomes were analyzed according to the risk stratification (irrespective of treatment group), patients in the standard-risk category had significantly superior EFS (P ¼ 0.007) and OS (P ¼ 0.006). These results are summarized in Table 5 .
Age also had a significant impact on survival parameters in a univariate analysis. Patients younger than 32 years (n ¼ 43) had superior outcome compared with those age of 32 years and older (n ¼ 44): 3-year EFS (50% (95% CI 36-69) vs 30% (95% CI 19-48), P ¼ 0.08) and OS (67% (95% CI 54-84) vs 37% (95% CI 25-55), P ¼ 0.0035) (Figure 4 ). There was no difference in EFS (P ¼ 0.89) or OS (P ¼ 0.52) in patients below 32 years, when results were compared in Table 1 Characteristics of patients in the 'donor' and the 'no donor' groups (23) 11 (28) NS ¼ nonsignificant. Cumulative relapse rate and nonrelapse-related (NRM) mortality. The 3-year cumulative relapse rate was higher in the 'no donor' group compared to the 'donor' group (61% (95% CI 44-79) vs 40% (95% CI 25-54), P ¼ 0.07). For high-risk patients, this became statistically significant in the 'no donor' group (83% (95% CI 60-100) vs 37% (95% CI 18-56), P ¼ 0.005), whereas no significant difference was observed in standard-risk patients (36% (95% CI 9-64) vs 38% (95% CI 10-67), P ¼ 0.84) or whose risk was not evaluable (60% (95% CI 9-100) vs 50% (95% CI 3-97), P ¼ 0.80). NRM was significantly high in the 'donor' group (29 vs 5%, P ¼ 0.004).
Outcome in Ph þ patients. Of the 17 Ph þ patients (19%), three patients did not have donors and were treated with chemotherapy only, while 14 patients had donors (HLA identical (n ¼ 5), matched unrelated (n ¼ 9)). The median age of this subgroup of patients at diagnosis was 38 years and all patients had a Pre-B immunophenotype. All patients with donors were transplanted (CR1 (n ¼ 13), CR2 (n ¼ 1)). The median time from the diagnosis to transplant was 7.5 months. All patients in the 'no donor' group relapsed, while the causes of failure in the 'donor' group were either treatment-related death (n ¼ 4) or relapse (n ¼ 2). The 3-year EFS and OS in the 'donor' group was 46% (95% CI 17-74) and 57% (95% CI 31-83), respectively. None of the patients in the 'no donor' group survived beyond 3 years. There was no difference in the 3-year OS of Ph þ patients observed compared to PhÀ patients (51% (95% CI 32-83) vs 52% (95% CI 41-65), P ¼ 0.7782) ( Figure 5 ).
Discussion
There have been no trials in the field of alloBMT in which patients with a matched sibling donor have been randomized between alloBMT vs chemotherapy. In the absence of a true randomization, genetic randomization is an established way of comparing alloBMT with chemotherapy or ABMT. 29 Matched pair analysis or comparative studies cannot eliminate potentially unknown selection biases. It is also important to analyze the results according to the intention-to-treat principle. 30 Failure to analyze by intention-to-treat can give misleading interpretations and biased treatment effects. Results that compare patients who actually received an alloBMT vs chemotherapy alone may show superiority of the former approach; however, these Table 3 3-Year EFS in the 'donor' and the 'no donor' groups according to risk stratification 
P=0.41 (log-rank test)
Time from diagnosis (months) Figure 2 Kaplan-Meier estimate of probability of % alive for all patients in the 'donor' group (46% at 3 years, 95% CI 31-61) compared with 'no donor' group (58% at 3 years, 95% CI 41-75). The marks on survival curves represent censoring points.
Role of alloBMT in adult ALL in CR1 V Gupta et al results do not take into account the morbidity experienced either due to relapse or deterioration in performance status, resulting in inability to deliver the intended alloBMT to these patients. There is only one study published in adult ALL that meets these criteria. 12 This study supported the role of alloBMT in CR1 in high-risk ALL. Our results did not show any survival advantage of applying a policy of performing alloBMT in all patients if a donor is available. In a subgroup analysis, there was no difference in the survival of PhÀ patients compared with Ph þ patients. Given the poor survival of Ph þ patients with chemotherapy alone, our treatment strategy seems to benefit this subgroup of patients.
It is worthwhile to point out some of the differences between our study and the LALA 87 study in relation to patient characteristics and study design. The control group in LALA 87 study was randomized between ABMT and maintenance chemotherapy, 12 while our comparable group was treated with chemotherapy alone. In our study, a higher proportion of patients (60%) belong to the high-risk category compared to the LALA 87 study (37%). While the criteria for risk stratification in these two studies are nearly the same, the cause of discordance may be related to differences in patient characteristics. The age of the study cohort in the LALA 87 trial was 15-40 years compared to 16-54 years in our study. Valid cytogenetics data were available only in 48% of patients enrolled in the LALA 87 study compared to 74% in our patient cohort. The frequency of Ph þ patients was 10% in LALA 87 study Figure 5 Kaplan-Meier estimate of probability of % alive according to Ph status, Ph þ patients (51% at 3 years, 95% CI 32-83) compared to PhÀ patients (52% at 3 years, 95% CI 41-65). The marks on survival curves represent censoring points.
Role of alloBMT in adult ALL in CR1
V Gupta et al compared to 19% in our study. These differences could have resulted in an underestimation of high-risk ALL in the French study. Our study cohort probably reflects a more accurate estimate of the proportion of high-risk patients in adults with ALL below the age of 55 years. The social healthcare system and centralized care of acute leukemia patients in our region eliminates referral or healthcare access bias from the present study and allows an opportunity to evaluate population-based outcome of adult ALL below the age of 55 years with this treatment strategy.
The main limitations of our study remain the retrospective nature and the small sample size, resulting in lack of sufficient power to demonstrate subtle differences between the two groups.
In a previous case-controlled study comparing alloBMT with chemotherapy, the results were superior for young patients (age 30 years or younger) in the alloBMT arm. 13 This was attributed to both a lower transplant-related mortality (32 vs 57%) and lower relapse rate (22 vs 32%) in favor of young patients in the alloBMT arm. Although patient's age 32 years and above had significantly inferior OS in our study, we did not find any difference in the survival outcomes in the 'donor' and the 'no donor' groups based on age.
It is noteworthy that the superiority of alloBMT in Ph þ ALL in the previous reports 31, 32 and our study predates the use of Imatinib Mesylate (Gleevec). Gleevec has shown significant activity in Ph þ ALL, although the beneficial effect is not durable. 33, 34 The studies exploring the combination of Gleevec with standard chemotherapeutic agents in Ph þ acute leukemias are under evaluation at present. Preliminary results of these studies indicate that this approach is feasible and well tolerated. 35 The indications of alloBMT in Ph þ ALL may evolve further once the long-term data from these studies become available. Also, 20-30% Ph þ patients still relapse after alloBMT. Whether this agent will have a further role in the setting of minimal residual disease especially after alloBMT is not known at present. This approach is currently being tested by the German GMALL study group in a multicenter study (personal communication, Dr OG Ottmann).
There is a substantial room for improvement with both chemotherapy as well as alloBMT approaches. Compared with chemotherapy, the antileukemic action of alloBMT is significantly higher in high-risk ALL; however, the principal limitation of alloBMT remains the nonrelapserelated mortality (NRM). Thus, improvements of alloBMT associated toxicity remains an important challenge in improving the outcome of these patients. In addition, the results of chemotherapy may further be improved by integrating newer targeted agents into conventional treatment protocols. Several of these approaches are currently under evaluation.
With the limitation of small sample size, our data suggest that only patients with Ph þ ALL may benefit from alloBMT. The policy of performing an alloBMT for patients with an available sibling donor has not resulted in better outcome in patients with PhÀ ALL. The currently ongoing large multicenter ALL trial (collaborative study between MRC and ECOG) should further define the role of alloBMT in the management of adult ALL. Role of alloBMT in adult ALL in CR1 V Gupta et al
